GO:0031724 CXCR5 chemokine receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031724 (CXCR5 chemokine receptor binding) is a molecular function describing the binding of a ligand to the CXCR5 chemokine receptor.
• The principal ligand for CXCR5 is CXCL13, and CXCL13-CXCR5 signaling is best known for organizing lymphoid follicles and guiding B cell and T follicular helper cell positioning.
• CXCR5 signaling is implicated in chronic pain and neuroinflammation, diabetes-accelerated atherosclerosis, autoimmune disease risk, and breast cancer.
• CXCR5 expression can be regulated by p53 in breast cancer cells and by TCR engagement through the mevalonate pathway in T follicular helper cells.
• Genetic variation at the DDX6-CXCR5 locus influences immune cell regulatory networks and salivary gland biology in autoimmunity.
• CRISPR knockout, knock-in, point-mutation, and overexpression models are key tools for dissecting CXCR5 ligand-receptor interactions and their downstream effects.
Description
GO:0031724, CXCR5 chemokine receptor binding, is a Gene Ontology molecular function term defined as binding to a CXCR5 chemokine receptor. CXCR5 is a G-protein-coupled receptor that directs the migration and positioning of B cells and T follicular helper cells within lymphoid tissues, and its best-characterized ligand is the chemokine CXCL13. The interaction between CXCL13 and CXCR5 is central to the formation of germinal centers and to the spatial organization of adaptive immune responses. Because this binding event controls cell trafficking, it has broad relevance for immunology, oncology, and neuroscience. Researchers study GO:0031724 to understand how chemokine gradients are interpreted by immune cells and how disruption of this axis contributes to autoimmunity, chronic pain, atherosclerosis, and cancer. The term is therefore a molecular entry point for linking ligand-receptor biochemistry to tissue-level pathology.
CXCR5 chemokine receptor binding At A Glance
| GO ID | GO:0031724 |
|---|---|
| GO term | CXCR5 chemokine receptor binding |
| Ontology | molecular_function |
| Synonym | CXCR5 chemokine receptor ligand; type 1 Burkitt's lymphoma receptor binding |
| Major function | Binding of a ligand, principally CXCL13, to the CXCR5 chemokine receptor |
| Primary ligand | CXCL13 |
| Receptor | CXCR5 (C-X-C chemokine receptor type 5) |
| Cellular context | B cells, T follicular helper cells, and other CXCR5-expressing cells |
| Disease relevance | Autoimmunity, chronic pain, atherosclerosis, breast cancer |
What Is GO:0031724?
In practical terms, GO:0031724 describes the molecular function of a ligand physically binding to the CXCR5 chemokine receptor. The QuickGO definition states that this term covers binding to a CXCR5 chemokine receptor. It is a molecular_function term, meaning it describes an activity at the molecular level rather than a whole biological process or a cellular structure. The synonym type 1 Burkitt's lymphoma receptor binding reflects the historical identification of CXCR5 in Burkitt's lymphoma cells. This binding event is the first step in CXCL13-CXCR5 signaling and is required for downstream receptor activation and chemotaxis.
Why Is CXCR5 chemokine receptor binding Important in Cell Biology?
CXCR5 chemokine receptor binding is important because it initiates a signaling axis that controls where immune cells go and how they organize into functional tissues. CXCL13-CXCR5 signaling is essential for the formation of germinal centers and for the positioning of T follicular helper cells and B cells during humoral immunity. When this binding is dysregulated, it contributes to autoimmune pathology, neuroinflammatory and chronic pain states, diabetes-accelerated atherosclerosis, and cancer progression. Understanding the molecular details of GO:0031724 therefore has direct implications for therapeutic targeting of chemokine-receptor interactions.
• CXCL13-CXCR5 binding organizes B cells and T follicular helper cells into germinal centers during immune responses.
• The CXCL13-CXCR5 axis is implicated in neuroinflammation and the pathogenesis of chronic pain and neurological diseases.
• S-nitrosylation-mediated coupling of G-protein alpha-2 with CXCR5 drives Hippo/YAP-dependent diabetes-accelerated atherosclerosis.
• Variants at the DDX6-CXCR5 autoimmune disease risk locus influence regulatory networks in immune cells and salivary gland.
• CXCR5 expression is p53-dependent in MCF-7 breast cancer cells, linking this receptor to cancer biology.
• TCR engagement modulates the mevalonate pathway to regulate T follicular helper cell generation, a process dependent on CXCR5 biology.
• ZNF382 controls neuropathic pain via epigenetic inhibition of Cxcl13 in DRG neurons, highlighting ligand regulation.
• Nlrp9b inflammasome restricts rotavirus infection in intestinal epithelial cells, showing broader roles of immune signaling in barrier tissues.
• CXCR5 binding is a tractable target for CRISPR-based functional studies of chemokine-receptor interactions.
• Understanding GO:0031724 supports development of therapeutics for autoimmune and inflammatory diseases.
Molecular Mechanism of CXCR5 chemokine receptor binding
Ligand recognition and binding
In simple terms: The ligand CXCL13 docks onto the CXCR5 receptor like a key fitting a lock.
CXCR5 chemokine receptor binding begins when the chemokine CXCL13 engages the extracellular loops and N-terminus of CXCR5. This interaction is the defining event of GO:0031724 and is required for receptor activation. CXCL13-CXCR5 signaling is a central axis in lymphoid tissue organization and immune cell positioning.
Receptor activation and G-protein coupling
In simple terms: Once the ligand binds, the receptor switches on a partner protein inside the cell.
Upon ligand binding, CXCR5 acts as a G-protein-coupled receptor and triggers downstream signaling. S-nitrosylation-mediated coupling of G-protein alpha-2 with CXCR5 has been shown to induce Hippo/YAP-dependent diabetes-accelerated atherosclerosis, demonstrating that post-translational modification of the receptor complex can shape signaling outcomes.
Regulation of CXCR5 expression
In simple terms: The amount of CXCR5 on the cell surface can go up or down depending on the cell's state.
CXCR5 expression is regulated at the transcriptional level. In MCF-7 breast cancer cells, CXCR5 expression is p53-dependent, linking a tumor suppressor to chemokine receptor abundance. In T follicular helper cells, TCR engagement modulates the mevalonate pathway to regulate their generation, a process that depends on appropriate CXCR5 expression.
Ligand availability and epigenetic control
In simple terms: The ligand side of the interaction is also controlled, so binding depends on how much CXCL13 is produced.
The availability of CXCL13 is regulated epigenetically. ZNF382 controls mouse neuropathic pain via silencer-based epigenetic inhibition of Cxcl13 in DRG neurons, showing that ligand production is a key control point for CXCR5 binding. In the intestine, the Nlrp9b inflammasome restricts rotavirus infection, illustrating how immune signaling components in barrier tissues can intersect with chemokine biology.
Genetic variation affecting the axis
In simple terms: Small changes in DNA near CXCR5 can alter how immune cells behave.
Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland, indicating that non-coding genetic variation can modulate the CXCR5 axis and contribute to autoimmune disease risk.
Key Genes Involved in GO:0031724 CXCR5 chemokine receptor binding
The following genes and proteins are central to CXCR5 chemokine receptor binding and its downstream biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CXCR5 | Chemokine receptor that binds CXCL13 | Core receptor for GO:0031724; target for knockout and knock-in studies |
| CXCL13 | Primary ligand for CXCR5 | Ligand whose expression is epigenetically regulated in pain models |
| GNAS | G-protein alpha-2 subunit coupling to CXCR5 | Mediates S-nitrosylation-dependent signaling in atherosclerosis |
| TP53 | Regulates CXCR5 expression | p53-dependent CXCR5 expression in breast cancer cells |
| DDX6 | RNA helicase at the DDX6-CXCR5 risk locus | Autoimmune disease risk locus influencing immune regulatory networks |
| ZNF382 | Transcriptional repressor of Cxcl13 | Controls neuropathic pain via epigenetic inhibition |
| NLrp9b | Inflammasome component | Restricts rotavirus infection in intestinal epithelial cells |
| YAP | Downstream effector of Hippo pathway | Mediates CXCR5-dependent atherosclerosis |
| BCL6 | T follicular helper cell transcription factor | Cooperates with CXCR5 in germinal center biology |
| PD-1 | T follicular helper cell marker | Co-expressed with CXCR5 in pathogenic T cells |
| CD4 | T cell co-receptor | Marks T follicular helper cells that express CXCR5 |
| CD19 | B cell marker | Identifies B cells responding to CXCL13 gradients |
| ICOS | T cell co-stimulator | Supports T follicular helper cell differentiation |
| IL-21 | Cytokine produced by T follicular helper cells | Downstream of CXCR5-dependent T-B interactions |
| RORγt | Transcription factor in lymphoid tissue inducer cells | Relevant to CXCL13-CXCR5 lymphoid organization |
| TNF | Pro-inflammatory cytokine | Contributes to neuroinflammatory contexts of CXCL13-CXCR5 signaling |
| IL-6 | Cytokine influencing T follicular helper cells | Linked to autoimmune T cell expansion |
| STAT3 | Signaling transcription factor | Downstream of cytokine signals in CXCR5+ T cells |
How Is CXCR5 chemokine receptor binding Regulated?
CXCR5 chemokine receptor binding is regulated at multiple levels. Receptor abundance is controlled transcriptionally; in MCF-7 breast cancer cells, CXCR5 expression is p53-dependent. In T follicular helper cells, TCR engagement modulates the mevalonate pathway to regulate their generation, indirectly influencing CXCR5-dependent positioning. Ligand availability is also regulated epigenetically, as ZNF382 represses Cxcl13 in DRG neurons to control neuropathic pain. Post-translational modification of the receptor complex, such as S-nitrosylation-mediated coupling of G-protein alpha-2 with CXCR5, can alter downstream signaling. Finally, genetic variation at the DDX6-CXCR5 locus can reshape regulatory networks in immune cells.
CXCR5 chemokine receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CXCR5 | Rheumatoid arthritis and autoimmunity | Knockout mouse or human T cell knockout |
| CXCL13 | Neuropathic pain and neuroinflammation | Conditional knockout in DRG neurons |
| GNAS | Diabetes-accelerated atherosclerosis | Point-mutation knock-in of S-nitrosylation site |
| DDX6 | Autoimmune disease risk locus | CRISPR knock-in of risk variants |
| TP53 | Breast cancer | p53 knockout in MCF-7 cells |
Autoimmunity and rheumatoid arthritis
Pathologically expanded peripheral T helper cells that express CXCR5 drive B cell responses in rheumatoid arthritis, linking CXCR5 chemokine receptor binding to autoimmune joint disease. Variants at the DDX6-CXCR5 autoimmune disease risk locus further influence regulatory networks in immune cells and salivary gland, supporting a role for this axis in autoimmunity.
Chronic pain and neurological disease
Chemokine CXCL13-CXCR5 signaling contributes to neuroinflammation and the pathogenesis of chronic pain and neurological diseases. In mouse models, ZNF382 controls neuropathic pain via silencer-based epigenetic inhibition of Cxcl13 in DRG neurons, showing that ligand regulation upstream of CXCR5 binding is functionally important.
Atherosclerosis and metabolic disease
S-nitrosylation-mediated coupling of G-protein alpha-2 with CXCR5 induces Hippo/YAP-dependent diabetes-accelerated atherosclerosis, demonstrating that CXCR5 signaling can drive vascular pathology in the context of metabolic disease.
Cancer
CXCR5 expression is p53-dependent in MCF-7 breast cancer cells, suggesting that CXCR5 chemokine receptor binding may be relevant to breast cancer biology and that loss of p53 could alter chemokine receptor levels.
From CXCR5 chemokine receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CXCR5 abolish ligand binding and immune cell positioning? | CXCR5 knockout cell line or mouse |
| Does a specific point mutation in CXCR5 alter ligand affinity? | Point-mutation knock-in of CXCR5 |
| Can a tagged CXCR5 be used to track receptor trafficking? | Tagged knock-in of CXCR5 |
| Does overexpression of CXCL13 increase CXCR5 signaling? | CXCL13 overexpression cell model |
| Do autoimmune risk variants at DDX6-CXCR5 alter regulatory networks? | CRISPR knock-in of risk alleles |
| Does p53 regulate CXCR5 expression in cancer cells? | p53 knockout or overexpression in MCF-7 cells |
How to Study the CXCR5 chemokine receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | CXCR5 surface expression and ligand binding | Immune cell phenotyping |
| CRISPR knockout screen | Genes required for CXCR5 signaling | Discovery of pathway modifiers |
| RNA-seq | Transcriptional changes downstream of CXCR5 | Regulatory network analysis |
| ATAC-seq | Chromatin accessibility at CXCR5 locus | Non-coding variant function |
| Surface plasmon resonance | Binding affinity of CXCL13 to CXCR5 | Biophysical characterization |
| Immunohistochemistry | Tissue localization of CXCR5+ cells | Lymphoid tissue organization |
| Mouse disease models | In vivo consequences of CXCR5 binding | Autoimmunity, pain, atherosclerosis |
Binding assays
Direct measurement of CXCL13 binding to CXCR5 can be performed using radioligand binding, surface plasmon resonance, or flow cytometry-based binding assays. These methods quantify the affinity and kinetics of the interaction defined by GO:0031724.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes that regulate CXCR5 chemokine receptor binding and downstream signaling. Such screens are particularly useful for uncovering modifiers of the CXCL13-CXCR5 axis in immune cells.
Transcriptomics and regulatory network analysis
RNA-seq and ATAC-seq can reveal how genetic variants at the DDX6-CXCR5 locus influence regulatory networks in immune cells and salivary gland. These approaches help connect non-coding variation to CXCR5 expression and function.
In vivo disease models
Mouse models of neuropathic pain, atherosclerosis, and autoimmunity are used to study the physiological consequences of CXCL13-CXCR5 signaling. Conditional knockouts and point-mutation knock-ins allow precise dissection of the pathway.
How CRISPR Can Be Used to Study GO:0031724 CXCR5 chemokine receptor binding
Knockout
CRISPR knockout of CXCR5 or CXCL13 can abolish ligand-receptor binding and reveal the contribution of GO:0031724 to immune cell positioning and disease. Knockout models are essential for validating causal roles in autoimmunity and cancer.
Point Mutation
Point-mutation knock-in can be used to dissect specific residues in CXCR5 that mediate ligand binding or G-protein coupling. For example, mutating the S-nitrosylation site in the G-protein alpha-2 coupling interface could test its role in atherosclerosis.
Knock-in
Knock-in of tagged CXCR5 or disease-risk variants at the DDX6-CXCR5 locus allows tracking of receptor trafficking and analysis of non-coding variant function in immune cells.
Overexpression
Overexpression of CXCL13 or CXCR5 can amplify signaling and is useful for studying downstream effects such as Hippo/YAP activation in atherosclerosis or T follicular helper cell expansion in autoimmunity.
How EDITGENE Supports CXCR5 chemokine receptor binding Research
Researchers studying CXCR5 chemokine receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand-receptor interactions, downstream signaling, or disease pathology. EDITGENE provides validated CRISPR tools and services to build precisely engineered cell models for such studies.
Contact EDITGENE today to design your custom CRISPR model for CXCR5 chemokine receptor binding research.
Frequently Asked Questions About CXCR5 chemokine receptor binding
What is CXCR5 chemokine receptor binding?
CXCR5 chemokine receptor binding (GO:0031724) is the molecular function of a ligand, primarily CXCL13, binding to the CXCR5 chemokine receptor.
What genes are involved in CXCR5 chemokine receptor binding?
Key genes include CXCR5, CXCL13, GNAS, TP53, DDX6, and ZNF382, among others.
What is the GO ID for CXCR5 chemokine receptor binding?
The Gene Ontology ID is GO:0031724.
What is the synonym for GO:0031724?
The synonym is type 1 Burkitt's lymphoma receptor binding.
How is CXCR5 chemokine receptor binding regulated?
It is regulated by p53-dependent transcription, epigenetic control of CXCL13, TCR-mevalonate signaling, and post-translational modifications such as S-nitrosylation.
What diseases are associated with CXCR5 chemokine receptor binding?
It is associated with rheumatoid arthritis, chronic pain, neuroinflammation, diabetes-accelerated atherosclerosis, and breast cancer.
How can CRISPR be used to study CXCR5 chemokine receptor binding?
CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models can dissect ligand binding, receptor trafficking, and downstream signaling.
What methods measure CXCR5 chemokine receptor binding?
Flow cytometry, surface plasmon resonance, radioligand binding, and CRISPR screens are commonly used.
Is CXCR5 chemokine receptor binding a molecular function or biological process?
It is a molecular_function term in the Gene Ontology.
What is the primary ligand for CXCR5?
CXCL13 is the primary ligand for CXCR5.
Conclusion
GO:0031724, CXCR5 chemokine receptor binding, defines a molecular interaction that sits at the heart of immune cell positioning and tissue organization. The CXCL13-CXCR5 axis is essential for germinal center formation and is implicated in autoimmunity, chronic pain, atherosclerosis, and cancer. Understanding how this binding event is regulated and how it can be targeted requires precise genetic models. CRISPR-based knockout, knock-in, point-mutation, and overexpression approaches, combined with functional screens and bioinformatics, provide a powerful toolkit for dissecting this pathway. EDITGENE supports researchers in building these models to accelerate discovery in chemokine biology and disease.
References
- 1. Zheng K et al.. 2024. Chemokine CXCL13-CXCR5 signaling in neuroinflammation and pathogenesis of chronic pain and neurological diseases.. Cell Mol Biol Lett 29(1):134 PMID: 39472796
- 2. Rao DA et al.. 2017. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis.. Nature 542(7639):110-114 PMID: 28150777
- 3. Chao ML et al.. 2021. S-nitrosylation-mediated coupling of G-protein alpha-2 with CXCR5 induces Hippo/YAP-dependent diabetes-accelerated atherosclerosis.. Nat Commun 12(1):4452 PMID: 34294713
- 4. Wiley MM et al.. 2025. Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland.. Ann Rheum Dis 84(9):1512-1527 PMID: 40447495
- 5. Ma L et al.. 2021. ZNF382 controls mouse neuropathic pain via silencer-based epigenetic inhibition of Cxcl13 in DRG neurons.. J Exp Med 218(12) PMID: 34762123
- 6. Zhu S et al.. 2017. Nlrp9b inflammasome restricts rotavirus infection in intestinal epithelial cells.. Nature 546(7660):667-670 PMID: 28636595
- 7. Mitkin NA et al.. 2015. p53-dependent expression of CXCR5 chemokine receptor in MCF-7 breast cancer cells.. Sci Rep 5:9330 PMID: 25786345
- 8. Wang L et al.. 2026. Modulation of the mevalonate pathway by TCR engagement regulates T follicular helper cell generation in homeostasis and autoimmunity.. Immunity 59(7):1911-1927.e12 PMID: 42134327
